NASDAQ:RLMD Relmada Therapeutics - RLMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.26 -0.06 (-2.59%) (As of 03/24/2023 02:46 PM ET) Add Compare Share Share Today's Range$2.00▼$2.2750-Day Range$2.32▼$4.7652-Week Range$1.81▼$38.68Volume214,279 shsAverage Volume282,525 shsMarket Capitalization$68.03 millionP/E RatioN/ADividend YieldN/APrice Target$20.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Relmada Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside840.4% Upside$20.50 Price TargetShort InterestHealthy4.85% of Shares Sold ShortDividend StrengthN/ASustainability-1.45Upright™ Environmental ScoreNews Sentiment-0.16Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.37) to ($3.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector159th out of 989 stocksPharmaceutical Preparations Industry62nd out of 480 stocks 3.2 Analyst's Opinion Consensus RatingRelmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, Relmada Therapeutics has a forecasted upside of 840.4% from its current price of $2.18.Amount of Analyst CoverageRelmada Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.85% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 8.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRelmada Therapeutics has received a 66.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for mood disorders" product. See details.Environmental SustainabilityThe Environmental Impact score for Relmada Therapeutics is -1.45. Previous Next 1.6 News and Social Media Coverage News SentimentRelmada Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for RLMD on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Relmada Therapeutics is held by insiders.Percentage Held by Institutions97.76% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($5.37) to ($3.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Relmada Therapeutics (NASDAQ:RLMD) StockRelmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.Read More Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comQ4 2022 Relmada Therapeutics Inc Earnings CallMarch 24, 2023 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 24, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 23, 2023 | finance.yahoo.comRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 22, 2023 | benzinga.comPreview: Relmada Therapeutics's EarningsMarch 22, 2023 | americanbankingnews.comRelmada Therapeutics (RLMD) Scheduled to Post Earnings on ThursdayMarch 19, 2023 | americanbankingnews.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $14.00 Consensus Target Price from BrokeragesMarch 17, 2023 | finance.yahoo.comRelmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023March 24, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 17, 2023 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the companyFebruary 16, 2023 | nasdaq.comDeep Track Capital Now Owns 9.43% of Relmada Therapeutics (RLMD)January 23, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Relmada Therapeutics (RLMD)January 9, 2023 | finance.yahoo.comRelmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical OfficerDecember 15, 2022 | finance.yahoo.comSergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just Picked Up 62% More SharesDecember 9, 2022 | msn.comLooking Into Relmada Therapeutics's Recent Short InterestDecember 8, 2022 | marketwatch.comRelmada Therapeutics Shares Plumb New Depths After Lead Program Setback >RLMDDecember 8, 2022 | marketwatch.comRelmada Therapeutics Shares Slide Premarket on Study Failure >RLMDDecember 8, 2022 | finance.yahoo.comRelmada Shares Nosedive As Another Depression Trial Goes Up In SmokeDecember 8, 2022 | finance.yahoo.comRelmada Therapeutics shares decline 40% on ThursdayNovember 30, 2022 | seekingalpha.comRelmada Therapeutics: Trading Below Cash With 2 Clinical Readouts AheadNovember 10, 2022 | finance.yahoo.comRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comWe Think Relmada Therapeutics (NASDAQ:RLMD) Needs To Drive Business Growth CarefullyOctober 14, 2022 | 247wallst.comRelmada Shares Plunge More Than 75% After Depression Drug Trial FailsOctober 13, 2022 | za.investing.comOppenheimer Cautions Against Relmada Therapeutics Trial OptimismOctober 13, 2022 | markets.businessinsider.comRelmada Stock Tumbles To 52-Week Low On Failed Depression TrialOctober 13, 2022 | seekingalpha.comRelmada stock crashes 78% as depression therapy REL-1017 fails phase 3 trialOctober 13, 2022 | marketwatch.comRelmada Therapeutics Shares Plummet on Phase 3 Study Failure >RLMDSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Company Calendar Last Earnings11/11/2021Today3/24/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RLMD CUSIPN/A CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees10Year Founded2004Price Target and Rating Average Stock Price Forecast$20.50 High Stock Price Forecast$60.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+783.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-78.53% Return on Assets-72.06% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio9.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.89 per share Price / Book0.29Miscellaneous Outstanding Shares30,100,000Free Float27,240,000Market Cap$69.83 million OptionableOptionable Beta0.15 Social Links Key ExecutivesSergio TraversaChief Executive Officer & DirectorMaged S. ShenoudaChief Financial OfficerPaolo ManfrediChief Scientific OfficerMarc L. de SomerSenior Vice President-Clinical DevelopmentCedric O'GormanChief Medical OfficerKey CompetitorsWerewolf TherapeuticsNASDAQ:HOWLImmunicNASDAQ:IMUXAnebulo PharmaceuticalsNASDAQ:ANEBGlycoMimeticsNASDAQ:GLYCSeelos TherapeuticsNASDAQ:SEELView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCSold 9,585 shares on 2/28/2023Ownership: 0.036%Parallax Volatility Advisers L.P.Sold 8,000 shares on 2/27/2023Ownership: 0.000%Alliancebernstein L.P.Bought 12,500 shares on 2/16/2023Ownership: 0.101%Point72 Middle East FZEBought 15,517 shares on 2/16/2023Ownership: 0.052%Boothbay Fund Management LLCBought 12,792 shares on 2/15/2023Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions RLMD Stock - Frequently Asked Questions Should I buy or sell Relmada Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RLMD, but not buy additional shares or sell existing shares. View RLMD analyst ratings or view top-rated stocks. What is Relmada Therapeutics' stock price forecast for 2023? 6 equities research analysts have issued 12 month price objectives for Relmada Therapeutics' stock. Their RLMD share price forecasts range from $4.00 to $60.00. On average, they expect the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 783.6% from the stock's current price. View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts. How have RLMD shares performed in 2023? Relmada Therapeutics' stock was trading at $3.49 on January 1st, 2023. Since then, RLMD stock has decreased by 33.5% and is now trading at $2.32. View the best growth stocks for 2023 here. When is Relmada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our RLMD earnings forecast. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its earnings results on Thursday, November, 11th. The company reported ($2.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.62) by $0.82. What ETFs hold Relmada Therapeutics' stock? ETFs with the largest weight of Relmada Therapeutics (NASDAQ:RLMD) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).Psyk Etf (PSYK). What is Relmada Therapeutics' stock symbol? Relmada Therapeutics trades on the NASDAQ under the ticker symbol "RLMD." Who are Relmada Therapeutics' major shareholders? Relmada Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Millennium Management LLC (3.53%), Two Sigma Investments LP (1.75%), Morgan Stanley (1.62%), Geode Capital Management LLC (1.62%), Mirae Asset Global Investments Co. Ltd. (0.93%) and Renaissance Technologies LLC (0.72%). Insiders that own company stock include Charles J Casamento, Charles J Casamento, Maged Shenouda, Paul Edward Kelly and Sergio Traversa. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Relmada Therapeutics' stock price today? One share of RLMD stock can currently be purchased for approximately $2.32. How much money does Relmada Therapeutics make? Relmada Therapeutics (NASDAQ:RLMD) has a market capitalization of $69.83 million. The company earns $-125,750,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. How can I contact Relmada Therapeutics? Relmada Therapeutics' mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The official website for the company is www.relmada.com. The company can be reached via phone at (786) 629-1376 or via email at mbecker@relmada.com. This page (NASDAQ:RLMD) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.